Diovan Paragraph IV Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Novartis' antihypertensive Diovan (valsartan) was filed Dec. 28, according to FDA's March 2 updated list of filings